The study consists of a screening/baseline period, a treatment period, and a posttreatment follow-up period. The study includes a periodic review of safety data, that will be independently analyzed by the Data Safety Independent Committee (DSMC) and will recommend how to proceed with the study. conditions: Multiple Myeloma in Relapse studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is an open label, multicenter, phase II study of Elranatamab as single agent. The primary aiming is to evaluate the efficacy of elranatamab monotherapy in participants with relapsed refractory multiple myeloma (RRMM) who had received prior treatment with immunomodulatory drugs, protease inhibitors, and anti-CD38 therapy and were refractory to the last line of therapy as evaluated with the rate of complete Response and Undetectable Measurable Residual Disease. Efficacy refers to the rate of Undetectable Measurable Residual Disease at 6 and 12 months as per International Myeloma Working Group (IMWG) criteria evaluated by the investigators. primaryPurpose: TREATMENT masking: NONE maskingDescription: None (Open Label) count: 50 type: ESTIMATED name: Elranatamab (PF-06863135) measure: To evaluate the rate of Undetectable Measurable Residual Disease (uMRD) at 6 and 12 months as per International Myeloma Working Group (IMWG) criteria evaluated by the investigators of elranatamab in patients with relapsed/refractory multiple myeloma. measure: To evaluate annually by NGF until loss of response, the rate of Undetectable Measurable Residual Disease (% of patients with MRD negative by NGF method and with a sensitivity level of 10-5) of elranatamab in patients with R/R multiple myeloma. measure: Incidence and severity Adverse Events (AEs) and Serious Adverse Event (SAEs) as assessed by changes in laboratory values in blood and biochemistry tests. measure: Incidence and severity Adverse Events (AEs) and Serious Adverse Event (SAEs) as assessed by changes in physical examination and ECOG performance status scale (0-5). measure: Incidence and severity Adverse Events (AEs) and Serious Adverse Event (SAEs) as assessed by changes in vital sign measurements. measure: Incidence and severity Adverse Events (AEs) and Serious Adverse Event (SAEs) as assessed by pregnancy test. measure: Incidence and severity Adverse Events (AEs) and Serious Adverse Event (SAEs) as assessed by changes in 12-lead ECG. measure: Incidence and severity Adverse Events (AEs) and Serious Adverse Event (SAEs) as assessed by changes in Echocardiogram / MUGA. measure: To determine Circulating Tumor Cells (CTC) at baseline to evaluate its prognostic value. measure: To determine serum BCMA levels and its correlation with response. measure: To do gene expression techniques (RNA sequencing and single cell sequencing studies) coupled with intelligent clinical and molecular data analysis (i.e. machine learning) to identify factors that could predict response to elranatamab. measure: To determine MRD value with alternative methods measure: To characterize patients' immune system measure: To define genomic determinants of response/resistance measure: To evaluate Overall Response Rate of elranatamab in patients with relapsed/refractory multiple myeloma. measure: To evaluate Duration of Response of elranatamab in patients with relapsed/refractory multiple myeloma. measure: To evaluate Time to first and best response of elranatamab in patients with relapsed/refractory multiple myeloma. measure: To evaluate Progression-free survival (PFS) of elranatamab in patients with relapsed/refractory multiple myeloma. measure: To evaluate Overall survival (OS) of elranatamab in patients with relapsed/refractory multiple myeloma. measure: To evaluate PFS in those patients who stop treatment because of sustained MRD-positive for 12 months of elranatamab in patients with relapsed/refractory multiple myeloma. measure: To evaluate OS in those patients who stop treatment because of sustained MRD-positive for 12 months of elranatamab in patients with relapsed/refractory multiple myeloma. measure: To evaluate the Incidence of neurologic effects related to elranatamab in patients with relapsed/refractory multiple myeloma. measure: To evaluate the Incidence of cytopenias and infections related to elranatamab in patients with relapsed/refractory multiple myeloma. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Clínico Universitario de Santiago ~ CHUS status: NOT_YET_RECRUITING city: Santiago De Compostela state: A Coruña zip: 15706 country: Spain name: Marta Sonia Gonzalez Perez, MD role: CONTACT name: Marta Sonia Gonzalez Perez, MD role: PRINCIPAL_INVESTIGATOR lat: 42.88052 lon: -8.54569 facility: Institut Catala d'Oncologia (ICO) Badalona - Hospital Universitari Germans Trias i Pujol status: NOT_YET_RECRUITING city: Badalona state: Barcelona zip: 08916 country: Spain name: Albert Oriol Rocafiguera, MD role: CONTACT name: Albert Oriol Rocafiguera, MD role: PRINCIPAL_INVESTIGATOR lat: 41.45004 lon: 2.24741 facility: Institut Catala d'Oncologia (ICO) Hospital Duran i Reynals status: NOT_YET_RECRUITING city: L'Hospitalet De Llobregat state: Barcelona zip: 08908 country: Spain name: Ana Sureda, MD role: CONTACT name: Ana Sureda, MD role: PRINCIPAL_INVESTIGATOR lat: 41.35967 lon: 2.10028 facility: Hospital Universitario Marqués de Valdecilla status: NOT_YET_RECRUITING city: Santander state: Cantabria zip: 39008 country: Spain name: Enrique M Ocio San Miguel, MD role: CONTACT name: Enrique M Ocio San Miguel, MD role: PRINCIPAL_INVESTIGATOR lat: 43.46472 lon: -3.80444 facility: Hospital Universitario de Jerez de la Frontera status: NOT_YET_RECRUITING city: Jerez De La Frontera state: Cádiz zip: 11407 country: Spain name: Sebastian Garzon Lopez, MD role: CONTACT name: Sebastian Garzon Lopez, MD role: PRINCIPAL_INVESTIGATOR lat: 36.68645 lon: -6.13606 facility: Hospital Son Llàtzer status: NOT_YET_RECRUITING city: Palma De Mallorca state: Illes Balears zip: 07198 country: Spain name: Joan LL Bargay, MD role: CONTACT name: Joan LL Bargay, MD role: PRINCIPAL_INVESTIGATOR lat: 39.56939 lon: 2.65024 facility: CHU de Gran Canaria Doctor Negrín status: NOT_YET_RECRUITING city: Las Palmas De Gran Canaria state: Las Palmas zip: 35010 country: Spain name: Alexia T Suarez Cabrera, MD role: CONTACT name: Alexia T Suarez Cabrera, MD role: PRINCIPAL_INVESTIGATOR lat: 28.09973 lon: -15.41343 facility: Hospital HM Sanchinarro status: NOT_YET_RECRUITING city: Sanchinarro state: Madrid zip: 28050 country: Spain name: Jaime Perez de Oteysa, MD role: CONTACT name: Jaime Perez de Oteysa, MD role: PRINCIPAL_INVESTIGATOR lat: 40.4165 lon: -3.70256 facility: Hospital Clínico Universitario Virgen de la Arrixaca status: NOT_YET_RECRUITING city: El Palmar state: Murcia zip: 30120 country: Spain name: Begoña Navarro de Almenzar, MD role: CONTACT name: Begoña Navarro de Almenzar, MD role: PRINCIPAL_INVESTIGATOR lat: 37.93939 lon: -1.16095 facility: Clinica Universidad Navarra (CUN) status: NOT_YET_RECRUITING city: Pamplona state: Navarra zip: 31008 country: Spain name: Jesus San Miguel Izquierdo, MD role: CONTACT phone: +34 948 296 296 email: sanmiguel@unav.es name: Paula Rodriguez Otero, MD role: PRINCIPAL_INVESTIGATOR lat: 42.81687 lon: -1.64323 facility: H. Clínic i Provincial de Barcelona status: NOT_YET_RECRUITING city: Barcelona zip: 08036 country: Spain name: Joan Bladé, MD role: CONTACT phone: +34 932275428 email: jblade@clinic.cat name: Laura Rossiñol, MD role: PRINCIPAL_INVESTIGATOR lat: 41.38879 lon: 2.15899 facility: Hospital de Cabueñes status: RECRUITING city: Gijón zip: 33394 country: Spain name: María Esther González García, MD role: CONTACT phone: + 34 985 18 50 00 name: María Esther González García, MD role: PRINCIPAL_INVESTIGATOR lat: 43.53573 lon: -5.66152 facility: Instituto de Investigación Sanitaria Hospital 12 de Octubre status: NOT_YET_RECRUITING city: Madrid zip: 28041 country: Spain name: Juan Jose Lahuerta, MD role: CONTACT phone: +34 91 779 28 39 email: jjlahuerta@telefonica.net lat: 40.4165 lon: -3.70256 facility: Hospital Clínico Universitario Salamanca status: RECRUITING city: Salamanca zip: 37007 country: Spain name: Mª Victoria Mateos, MD role: CONTACT phone: +34 923 291 100 phoneExt: 55384 email: mvmateos@usal.es name: Verónica González de la Calle, MD role: CONTACT phone: +34 923 291 100 phoneExt: 55629 email: vgcalle@saludcastillayleon.es name: Mª Victoria Mateos, MD role: PRINCIPAL_INVESTIGATOR lat: 40.96882 lon: -5.66388 facility: C.H. de Toledo (Virgen de la Salud) status: NOT_YET_RECRUITING city: Toledo zip: 45005 country: Spain name: Luis Felipe Casado Montero, MD role: CONTACT name: Luis Felipe Casado Montero, MD role: PRINCIPAL_INVESTIGATOR lat: 39.8581 lon: -4.02263 hasResults: False